Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2001 October;92(5) > Minerva Medica 2001 October;92(5):325-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

ORIGINAL ARTICLES  


Minerva Medica 2001 October;92(5):325-8

language: English

Plasma platelet activating factor in nephrotic syndrome

Camici M., Sagripanti A.


PDF  


Background. The mechanism of proteinuria in nephrotic syndrome is unknown. The plasma behaviour of platelet-activating factor (ng/ml) in nephrotic and normal people has been evaluated.
Methods. A total of 21 patients with nephrotic proteinuria due to glomerular pathology and 20 subjects as normal control people have been studied. Plasma PAF level is evaluated by (125I) RIA Kit (Du Pont NEN).
Results. Patients with glomerular proteinuria appeared to have a significant increase (p<0.05) plasma PAF bioactivity: 116.28±49.6 ng/ml versus 41.4±14.9 ng/ml of normal subjects.
Conclusions. The study shows that PAF may be involved in the mechanism of genesis of human glomerular proteinuria.

top of page

Publication History

Cite this article as

Corresponding author e-mail